Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | STK-009 |
Trade Name | |
Synonyms | STK009|STK009 |
Drug Descriptions |
STK-009 is an IL-2 mutein that stimulates a modified form of IL-2 receptor beta (IL-2R beta) while not stimulating wild-type IL-2R beta, potentially leading to enhanced antitumor response in combination with CAR T cells expressing the modified IL-2R beta (Cancer Res (2022) 82 (12_Supplement): 2824). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
STK-009 | STK-009 | 0 | 0 |
STK-009 + SYNCAR-001 | STK-009 SYNCAR-001 | 0 | 1 |